Cathepsin B, a prognostic indicator in lymph node-negative breast carcinoma patients: Comparison with cathepsin D, cathepsin L, and other clinical indicators

Clinical Cancer Research

Volumn 6, Issue 2, 2000, Pages 578-584

  Lah, Tamara ^a   Čerček, Miha ^a   Blejec, Andrej ^a   Kos, Janko ^b   Gorodetsky, Ella ^c   Somers, Robert ^c   Daskal, Ierachmiel ^c  

^a NATIONAL INSTITUTE OF BIOLOGY   (Slovenia)

^b KRKA D D   (Slovenia)

^c ALBERT EINSTEIN MEDICAL CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CATHEPSIN B; CATHEPSIN D; CATHEPSIN L; ESTROGEN RECEPTOR; PROGESTERONE RECEPTOR; STEROID RECEPTOR;

ADULT; AGED; ARTICLE; BREAST CARCINOMA; CANCER GRADING; CANCER RECURRENCE; CANCER STAGING; CANCER SURVIVAL; CONTROLLED STUDY; DNA DETERMINATION; ENZYME ACTIVITY; FEMALE; HISTOPATHOLOGY; HUMAN; HUMAN TISSUE; LYMPH NODE METASTASIS; MAJOR CLINICAL STUDY; PRIORITY JOURNAL; PROGNOSIS; RISK ASSESSMENT; TUMOR VOLUME;

ADULT; AGED; AGED, 80 AND OVER; BREAST NEOPLASMS; CATHEPSIN B; CATHEPSIN D; CATHEPSINS; CYSTEINE ENDOPEPTIDASES; ENDOPEPTIDASES; FEMALE; HUMANS; MIDDLE AGED; NEOPLASM INVASIVENESS; NEOPLASM STAGING; PREDICTIVE VALUE OF TESTS; PROGNOSIS; RECEPTORS, ESTROGEN; RECEPTORS, PROGESTERONE; RECURRENCE; SURVIVAL ANALYSIS; TIME FACTORS; TUMOR MARKERS, BIOLOGICAL;

EID: 0343340434     PISSN: 10780432     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (30)

1. Elledge, R. M., and McGuire, W. L. Prognostic factors and therapeutic decisions in auxiliary node-negative breast cancer. Annu. Rev. Med., 44: 201-210, 1993.
2. Graeff, H., Harbeck, N., Pache, L., Wilhem, O., Janicke, F., and Schmitt, M. Prognostic impact and clinical relevance of tumor-associated proteases in breast cancer. Fibnnolysis, 6: 45-53, 1992.
3. Sloane, B. F., Moin, K., and Lah, T. T. Regulation of lysosomal endopeptidases in malignant neoplasia. In: T. G. Pretlow and T. H. Pretlow (eds.), Biochemical and Molecular Aspects of Selected Cancers, pp. 411-466. New York: Academic Press, 1994.
4. Ren, W. P., and Sloane, B. F. Cathepsins D, and B in breast cancer. In: R. Dickson, and M. Lippman (eds.), Mammary Tumor Cell Cycle, Differentiation and Metastasis, pp. 325-352. Boston, MA: Kluwer Academic Publishers, 1996.
5. Garcia, M., Platet, N., Liaudet, E., Laurent, V., Derocq, D., Brouillet, J-P., and Rochefort, H. Biological and clinical significance of cathepsin D in breast cancer metastasis. Stem Cells, 14: 642-650, 1996.
6. Lah, T. T., and Kos, J. Cysteine proteinases in cancer progression and their clinical relevance for prognosis. Biol. Chem., 379: 125-130, 1998.
7. r 52,000 cathepsin D and poor prognosis in primary human breast cancer. Cancer Res., 49: 6008-6014, 1989.
8. Rochefort, H. Cathepsin D in breast cancer: a tissue marker associated with metastasis. Eur. J. Cancer, 28A: 1780-1783, 1992.
9. Ravdin, P. M. Evaluation of cathepsin D as a prognostic factor in breast cancer. Breast Cancer Res. Treat., 24: 219-226, 1993.
10. Lah, T. T., Kokalj-Kunovar, M., Štrukelj, B., Pungerčar, J., Magajna, D., Drobnič-Košorok, M., Kastelic, L., Babnik, J., Golouh, R., and Turk, V. Stefins and lysosomal cathepsins B, L and D in human breast carcinoma. Int. J. Cancer, 50: 36-44, 1992.
11. Lah, T. T., Čerček, M., Kos, J., Lowder, J., Gorodetsky, E., and Daskal, I. Epidermal growth factor receptor, Her-2/neu and cathepsins D, B and L as possible prognostic factors in breast carcinoma. Proc. of 19th Annual San Antonio Breast Cancer Symposium. San Antonio, Texas. Breast Cancer Res. Treat., 41: 24, 1997.
12. Lah, T. T, Kos, J., Blejec, A., Frkovič-Grazio, S., Golouh, R., Vrhovec, I., and Turk, V. The expression of lysosomal proteinases and their inhibitors in breast cancer: possible relationship to prognosis of the disease. Pathol. Oncol. Res., 3: 89-99, 1997.
13. Thomssen, C., Schmitt, M., Goretzki, L., Oppelt, P., Pache, L., Dettmar, P., Janicke, F., and Graeff, H. Prognostic value of the cysteine proteases cathepsin B and cathepsins L in human breast cancer. Clin. Cancer Res., 1: 741-746, 1995.
14. Foekens, J., Kos, J., Peters, H. A., Krašovec, M., Look, M. P., Cimerman, N., Meijer-van-Gelder, M., Henzen-Logmans, S. C., Putten, W. L. J., and Klijn, J. G. M. Prognostic significance of Cathepsins B and L in primary human breast cancer. J. Clin. Oncol., 16: 1013-1021, 1998.
15. EORTC Breast Cancer Cooperative Group. Revision of the standards for the assessments of hormone receptors in human breast cancer. Eur. J. Cancer, 16: 1513-1515, 1980.
16. Elston, C. W., and Ellis, O. I. Pathological prognostic factors in breast cancer. I. The value of histological grade in breast cancer: experience from a large study with long-term follow-up. Histopathology, 19: 403-410, 1991.
17. Kos, J., Šmid, A., Krašovec, M., Svetic, B., Lenarčič, B., Vrhovec, L, Škrk, J., and Turk, V. Lysosomal proteases Cats D, B. H, L and their inhibitors Stefins A and B in head and neck cancer. Biol. Chem. Hoppe-Seyler, 378: 401-405, 1995.
18. Barrett, A. J., and Kirschke, H. Cathepsin B, Cathepsin H, and Cathepsin L. Methods Enzymol., 80: 535-561, 1981.
19. Camplejohn, R. S., Ash, C. M., Gillet, C. E., Raikundalia, B., Barnes, D. M., Gregory, W. M., Richards, M. A., and Millis, R. R. The prognostic significance of DNA flow cytometry in breast cancer: results from 881 patients treated in a single centre. Br. J. Cancer, 71: 140-145, 1995.
20. Norušis, J. M. SPSS for Windows Base System. Users Guide Release 6.0, p. 19. Chicago: SPSS Inc., 1993.
21. Kaplan, E. L., and Meier, P. Nonparametric estimation from incomplete observation. J. Am. Stat. Assoc., 53: 457-481, 1958.
22. Cox, D. R. Regression models and life tables. J. R. Stat. Soc., 34: 187-220, 1972.
23. Lah, T. T, Calaf, G., Kalman, E., Shinde, B. G., Somers, R., Russo, J., Jarocz, D., Zabrecky, J., and Daskal, I. Cathepsins D, B, and L in human breast carcinoma and in transformed cells. J. Biol. Chem. Hoppe-Seyler, 376: 357-363, 1995.
24. Lah, T. T, Calaf, G., Kalman, E., Shinde, G., Somers, R., Estrada, S., Salero, E., Russo, J., Jarocz, D., Zabrecky, J., and Daskal, I. Differential regulation of cathepsins D, B, and L in transformed human breast epithelial cells (HBEC) with increased invasiveness. Breast Cancer Res. Treat., 39: 221-233, 1996.
25. Budihna, M., Škrk, J., Zakotnik, B., Gabrijelcic, D, and Lindtner, J. Prognostic value of total cathepsin B in invasive ductal carcinoma of the breast. Eur. J. Cancer, 31A: 661-664, 1995.
26. Westley, B. R., and May, F. E. B. Cathepsin D and breast cancer. Eur. J. Cancer, 32A: 15-24, 1996.
27. Ferrandina, G., Scambia, G., Bardelli, F., Panici, P. B., Mancuso, S., and Messori, A. Relationship between cathepsin D content and disease-free survival in node-negative breast cancer patients: a meta-analysis. Br. J. Cancer, 76: 661-666, 1997.
28. Shiqing Y., Sameni, M., and Sloane, B. Cathepsin B in human tumor progression. Biol. Chem., 379: 113-123, 1998.
29. Dehrmann, F. M., Elliott, E., and Denisson, C. Reductive activation markedly increased the stability of cathepsins B and L to extracellular ionic conditions. Biol. Chem. Hoppe-Seyler, 377: 391-394, 1996.
30. Saad, Z., Bramwell, V. H. C., Wilson, S. M., O'Malley, F. P., Jeacock, J., and Chambers, A. F. Expression of genes that contribute to proliferative and metastatic ability in breast cancer resected during various menstrual phases. Lancet, 351: 1170-1173, 1998.